Lori Muffly Profile picture
Jun 15, 2022 17 tweets 21 min read Read on X
🚥 #leukemia #ASH21 🛎️ Last call for poster #️5️ 〰️ Graaph-2014 study ➕ adding Nelarabine to chemo for #ALL pts 🔹 #OncTwitter w/ @LoriMuffly & @LuskinMarlise 🔸#CME from @BonumCe 🔗bit.ly/3FIOane 🔸Supported by edu grant Jazz Pharma twitter.com/i/broadcasts/1…
2/🟠Get your 🆓 #CME
CME ℹ️👉 bit.ly/3FIOane

#MedTwitter #OncTwitter #leusm
✔️What are your credentials❓
3/ 🏆#CME credit provided by @IntegrityCE
🤝In partnership w/ @BonumCe

⏱️ Please answer! ⏱️
🟢 PRE-polls before 💬
🔴POST-polls after 💬
🟠or🔗 bit.ly/3FIOane for #CME ℹ️

👇CME info 👇 Image
4/🟢PRE Poll 1️⃣
#BonumCE #OncTwitter #MedTwitter
🟠#CME bit.ly/3FEdvic

🟢 Which of the following is best describes outcomes associated with addition of 1 cycle nelarabine in adults with ALL based on the UKALL14 study?
5/ 🟢PRE Poll 2️⃣
#BonumCE #OncTwitter #MedTwitter
🟠#CME bit.ly/3FEdvic

🟢 An exploratory analysis of the UKALL14 study found that patients with T-cell ALL with absence of biallelic TCR𝛄deletion (ABD) were associated with which of the following outcomes?
6/🟢PRE Poll 3️⃣
#BonumCE #OncTwitter #MedTwitter
🟠#CME bit.ly/3FEdvic

🟢 Reduction in treatment intensity by omission of high-dose cytarabine from two cycles of of first-line therapy on the GRAAPH 2014 protocol for Ph+ ALL is associated with:
7/ #ALL #BonumCE #ASH21
📝Omission of cytarabine was associated with 📈 risk of relapse in adults enrolled in the GRAAPH 2014 phase 3 RCT in Ph+ ALL

🧬28 patients had NGS at relapse
🧬71% of patients had a mutation identified
🧬50% of mutations identified involved T315I Image
8/ #ALL #BonumCE #ASH21
📝UKALL14 Phase 3 RCT adding 1 cycle of post-remission nelarabine in adult 👥 with newly diagnosed T-cell ALL
🙅🏽‍♂️No Δ in EFS or OS in 👥 receiving SOC compared with 👥 receiving SOC ➕ 1 cycle of nelarabine
👇 Image
9/🔴POST Poll 1️⃣
#BonumCE #OncTwitter #MedTwitter
🟠#CME bit.ly/3sz5upH

🔴 Which of the following is best describes outcomes associated with addition of 1 cycle nelarabine in adults with ALL based on the UKALL14 study?
10/🔴POST Poll2️⃣
#BonumCE #OncTwitter
🟠#CME bit.ly/3sz5upH

🔴 An exploratory analysis of the UKALL14 study found that patients with T-cell ALL with absence of biallelic TCR𝛄deletion (ABD) were associated with which of the following outcomes?
11/🔴POST Poll 3️⃣
#MedTwitter #Webinar
🟠#CME bit.ly/3sz5upH

🔴 Reduction in treatment intensity by omission of high-dose cytarabine from two cycles of of first-line therapy on the GRAAPH 2014 protocol for Ph+ ALL is associated with:
12/ ⚠️ Don’t forget to claim your 🆓 #CME @AmerMedicalAssn credit 🎫 bit.ly/3FIOane

Thank you for joining our #ALL #leukemia CME series w/ @BonumCe 💕
13/ 💁Need more ℹ️❓
🆓 Want more #CME

#ICYMI 📽️ me, @RyanCassaday & Luke Maese, DO addressed asparaginase adherence, mgmt, & toxicities 🗓️

Catch our #ALL #leukemia #webinar here ⬇️

14/ Deeper dive? 🏊 Check out the rest of the poster series for more #ALL 📚 and #CME 🏆

🪧 1️⃣ - Results: Ph 2/3 recomb-ERW w @RyanCassaday & Luke Maese, DO @huntsmancancer

twitter.com/i/events/15299…
15/ #ICYMI #ALL 🪧 Poster 2️⃣ w @RyanCassaday & Luke Maese, DO @huntsmancancer review studies of #blinatumomab 💎AALL1331 @COGorg 💎Graall-2014-QUEST @NicBoissel

twitter.com/i/events/15299…
16/ #ICYMI #ALL 🪧 Poster 3️⃣: UKALL 2003 ➕10yr data GMALL 8/2013 of ND ALL/LBL with me and @LuskinMarlise

twitter.com/i/events/15367…
17/ #ICYMI #ALL 🪧 Poster 4️⃣: INITIAL-1 trial 🔹 EWALL-INO study 🔹 SWOG 1318 trial 🔹 #OncTwitter with @LuskinMarlise and me🔸#CME

twitter.com/i/events/15370…

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Lori Muffly

Lori Muffly Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

:(